Mylan Agrees Not to Introduce Generic Mirapex Until After Patent Expires in October

Mylan Pharmaceuticals Inc. agreed not to introduce a generic version of Boehringer Ingelheim’s Parkinson’s disease treatment Mirapex (pramipexole dihydrochloride tablets) until after Oct. 8, pursuant to a stipulated consent judgment entered in New Jersey federal court (Boehringer Ingelheim International GMBH v. Mylan Pharmaceuticals Inc.).

In the consent judgment entered Aug. 18 in the U.S. District Court for the District of New Jersey, Mylan also acknowledged that its abbreviated new drug application to make a generic version of infringed Boehringer’s patent, U.S. Patent No. 4,886,812 (the ‘812 patent), which does not expire until Oct. 8.

Mylan had submitted an ...